StollerJK, HupertzV, AboussouanLS, et al.Alpha-1 antitrypsin deficiency. In: GeneReviews®. (AdamMP, FeldmanJ, MirzaaGM, eds) Seattle, Washington: University of Washington, Seattle; 2006; pp. 1993–2024.
2.
FerrarottiI, BaccheschiJ, ZorzettoM, et al.Prevalence and phenotype of subjects carrying rare variants in the Italian registry for alpha1-antitrypsin deficiency. J Med Genet, 2005; 42(3):282–287; doi: 10.1136/jmg.2004.023903
3.
McElvaneyOJ, CarrollTP, FranciosiAN, et al.Consequences of abrupt cessation of alpha1-antitrypsin replacement therapy. N Engl J Med, 2020; 382(15):1478–1480; doi: 10.1056/NEJMc1915484
4.
AielloM, FantinA, LongoC, et al.Clinical manifestations in patients with PI*MMMalton genotypes. A matter still unsolved in alpha-1 antitrypsin deficiency. Respirol Case Rep, 2020; 8(3):e00528; doi: 10.1002/rcr2.528
5.
SennO, RussiEW, ImbodenM, et al.alpha1-Antitrypsin deficiency and lung disease: risk modification by occupational and environmental inhalants. Eur Respir J, 2005; 26(5):909–917; doi: 10.1183/09031936.05.00021605
6.
American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med, 2003; 168(7):818–900; doi: 10.1164/rccm.168.7.818
7.
PellegrinoR, ViegiG, BrusascoV, et al.Interpretative strategies for lung function tests. Eur Respir J, 2005; 26(5):948–968; doi: 10.1183/09031936.05.00035205
8.
SilvaM, LeddaRE, SchieblerM, et al.Frequency and characterization of ancillary chest CT findings in COVID-19 pneumonia. Br J Radiol, 2021; 94(1118):20200716; doi: 10.1259/bjr.20200716
9.
BohannonRW, CrouchR. Minimal clinically important difference for change in 6-minute walk test distance of adults with pathology: a systematic review. J Eval Clin Pract, 2017; 23(2):377–381; doi: 10.1111/jep.12629
JaroschI, HitzlW, KoczullaAR, et al.Comparison of exercise training responses in COPD patients with and without Alpha-1 antitrypsin deficiency. Respir Med, 2017; 130:98–101; doi: 10.1016/j.rmed.2017.07.009
12.
ChapmanKR, BurdonJG, PiitulainenE, et al.; RAPID Trial Study Group. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet, 2015; 386(9991):360–368; doi: 10.1016/S0140-6736(15)60860-1
13.
PerotinJM, LeroyS, MarquetteCH, et al.; REVOLENS Study Group. Endobronchial coil treatment in severe emphysema patients with alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis, 2018; 13:3645–3649; doi: 10.2147/COPD.S176366
14.
Barros-TizónJC, TorresML, BlancoI, et al.; Investigators of the rEXA study group. Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy. Ther Adv Respir Dis, 2012; 6(2):67–78; doi: 10.1177/1753465812438387
15.
LiebermanJ. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest, 2000; 118(5):1480–1485; doi: 10.1378/chest.118.5.1480
16.
DirksenA, PiitulainenE, ParrDG, et al.Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J, 2009; 33(6):1345–1353; doi: 10.1183/09031936.00159408
17.
FraughenDD, GhoshAJ, HobbsBD, et al.Augmentation therapy for severe alpha-1 Antitrypsin deficiency improves survival and is decoupled from spirometric decline-a multinational registry analysis. Am J Respir Crit Care Med, 2023; 208(9):964–974; doi: 10.1164/rccm.202305-0863OC
